Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mometasone/olopatadine - Glenmark Pharmaceuticals

Drug Profile

Mometasone/olopatadine - Glenmark Pharmaceuticals

Alternative Names: GSP 301-1 NS; GSP 301-2 NS; GSP-301; Mometasone furoate/olapatadine hydrochloride; Olopatadine/mometasone; RYALTRIS; Ryaltris

Latest Information Update: 08 May 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Glenmark Pharmaceuticals Ltd
  • Class Anti-inflammatories; Antiallergics; Antihistamines; Dibenzoxepins; Glucocorticoids; Pregnadienediols; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists; Histamine H1 receptor antagonists; Leukotriene B4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Allergic rhinitis; Perennial allergic rhinitis; Seasonal allergic rhinitis

Most Recent Events

  • 03 May 2023 Launched for Seasonal allergic rhinitis (In adolescents, In children, In adults) in Canada (Intranasal)
  • 10 Feb 2023 Launched for Allergic rhinitis in South Korea (Intranasal), prior to February 2023
  • 23 Sep 2022 Registered for Seasonal allergic rhinitis (In adolescents, In adults, In children) in Canada (Intranasal)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top